User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Treatment landscape of metastatic prostate cancer: the role of radium-223.

Primary tabs

Dermine, Alexandre [UCL] Machiels, Jean-Pascal [UCL]

The landscape of metastatic prostate cancer has changed recently with the availability of six new molecules showing an overall survival benefit. The development of compounds able to decrease the rate of complications from bone metastasis has also led to improvements in overall morbidity associated with this disease. In this paper, we briefly review the currently available drugs indicated in the treatment of metastatic prostate cancer, focusing on the place of the radiopharmaceutical agent radium-223 and its very unique mechanism of action and safety profile.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2017
Language Anglais
Journal information "Acta Clinica Belgica" - Vol. 72, no.1, p. 19-23 (2016)
Peer reviewed yes
Publisher Taylor & Francis ((United Kingdom) Abingdon)
issn 1784-3286
e-issn 2295-3337
Publication status Publié
Affiliations UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - (SLuc) Unité d'oncologie médicale
Keywords Metastatic castrate-resistant prostate cancer ; Radiopharmaceutical ; Radium-223
Links
  1. Siegel Rebecca L., Miller Kimberly D., Jemal Ahmedin, Cancer statistics, 2015 : Cancer Statistics, 2015, 10.3322/caac.21254
  2. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., Forman D., Bray F., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, 10.1016/j.ejca.2012.12.027
  3. Bubendorf Lukas, Schöpfer Alain, Wagner Urs, Sauter Guido, Moch Holger, Willi Niels, Gasser Thomas C., Mihatsch Michael J., Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients, 10.1053/hp.2000.6698
  4. Keller Evan T., Zhang Jian, Cooper Carlton R., Smith Peter C., McCauley Laurie K., Pienta Kenneth J., Taichman Russell S., 10.1023/a:1015599831232
  5. Weinfurt K. P., Li Y., Castel L. D., Saad F., Timbie J. W., Glendenning G. A., Schulman K. A., The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, 10.1093/annonc/mdi122
  6. Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger, Goessl Carsten, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, 10.1016/s0140-6736(10)62344-6
  7. Tannock Ian F., de Wit Ronald, Berry William R., Horti Jozsef, Pluzanska Anna, Chi Kim N., Oudard Stephane, Théodore Christine, James Nicholas D., Turesson Ingela, Rosenthal Mark A., Eisenberger Mario A., Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, 10.1056/nejmoa040720
  8. Petrylak Daniel P., Tangen Catherine M., Hussain Maha H.A., Lara Primo N., Jones Jeffrey A., Taplin Mary Ellen, Burch Patrick A., Berry Donna, Moinpour Carol, Kohli Manish, Benson Mitchell C., Small Eric J., Raghavan Derek, Crawford E. David, Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, 10.1056/nejmoa041318
  9. Sweeney Christopher J., Chen Yu-Hui, Carducci Michael, Liu Glenn, Jarrard David F., Eisenberger Mario, Wong Yu-Ning, Hahn Noah, Kohli Manish, Cooney Matthew M., Dreicer Robert, Vogelzang Nicholas J., Picus Joel, Shevrin Daniel, Hussain Maha, Garcia Jorge A., DiPaola Robert S., Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, 10.1056/nejmoa1503747
  10. Gravis Gwenaelle, Fizazi Karim, Joly Florence, Oudard Stéphane, Priou Franck, Esterni Benjamin, Latorzeff Igor, Delva Remy, Krakowski Ivan, Laguerre Brigitte, Rolland Fréderic, Théodore Christine, Deplanque Gael, Ferrero Jean Marc, Pouessel Damien, Mourey Loïc, Beuzeboc Philippe, Zanetta Sylvie, Habibian Muriel, Berdah Jean François, Dauba Jerome, Baciuchka Marjorie, Platini Christian, Linassier Claude, Labourey Jean Luc, Machiels Jean Pascal, El Kouri Claude, Ravaud Alain, Suc Etienne, Eymard Jean Christophe, Hasbini Ali, Bousquet Guilhem, Soulie Michel, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, 10.1016/s1470-2045(12)70560-0
  11. James ND, J Clin Oncol, 33 (2015)
  12. Parker C., Gillessen S., Heidenreich A., Horwich A., Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 10.1093/annonc/mdv222
  13. de Bono Johann Sebastian, Oudard Stephane, Ozguroglu Mustafa, Hansen Steinbjørn, Machiels Jean-Pascal, Kocak Ivo, Gravis Gwenaëlle, Bodrogi Istvan, Mackenzie Mary J, Shen Liji, Roessner Martin, Gupta Sunil, Sartor A Oliver, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, 10.1016/s0140-6736(10)61389-x
  14. Kantoff Philip W., Higano Celestia S., Shore Neal D., Berger E. Roy, Small Eric J., Penson David F., Redfern Charles H., Ferrari Anna C., Dreicer Robert, Sims Robert B., Xu Yi, Frohlich Mark W., Schellhammer Paul F., Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, 10.1056/nejmoa1001294
  15. Fizazi Karim, Scher Howard I, Molina Arturo, Logothetis Christopher J, Chi Kim N, Jones Robert J, Staffurth John N, North Scott, Vogelzang Nicholas J, Saad Fred, Mainwaring Paul, Harland Stephen, Goodman Oscar B, Sternberg Cora N, Li Jin Hui, Kheoh Thian, Haqq Christopher M, de Bono Johann S, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, 10.1016/s1470-2045(12)70379-0
  16. Ryan Charles J, Smith Matthew R, Fizazi Karim, Saad Fred, Mulders Peter F A, Sternberg Cora N, Miller Kurt, Logothetis Christopher J, Shore Neal D, Small Eric J, Carles Joan, Flaig Thomas W, Taplin Mary-Ellen, Higano Celestia S, de Souza Paul, de Bono Johann S, Griffin Thomas W, De Porre Peter, Yu Margaret K, Park Youn C, Li Jinhui, Kheoh Thian, Naini Vahid, Molina Arturo, Rathkopf Dana E, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, 10.1016/s1470-2045(14)71205-7
  17. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  18. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  19. Antonarakis Emmanuel S., Lu Changxue, Wang Hao, Luber Brandon, Nakazawa Mary, Roeser Jeffrey C., Chen Yan, Mohammad Tabrez A., Chen Yidong, Fedor Helen L., Lotan Tamara L., Zheng Qizhi, De Marzo Angelo M., Isaacs John T., Isaacs William B., Nadal Rosa, Paller Channing J., Denmeade Samuel R., Carducci Michael A., Eisenberger Mario A., Luo Jun, AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer, 10.1056/nejmoa1315815
  20. Coleman R. E., Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity, 10.1158/1078-0432.ccr-06-0931
  21. Halabi Susan, Vogelzang Nicholas J., Kornblith Alice B., Ou San-San, Kantoff Philip W., Dawson Nancy A., Small Eric J., Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer, 10.1200/jco.2007.15.0367
  22. Corey E, Clin Cancer Res, 9, 295 (2003)
  23. Guise Theresa A., Antitumor effects of bisphosphonates: Promising preclinical evidence, 10.1016/j.ctrv.2008.03.006
  24. Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J. L., Vinholes J. J., Goas J. A., Chen B., A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma, 10.1093/jnci/94.19.1458
  25. Zhang Jian, Dai Jinlu, Qi Yinghua, Lin Din-Lii, Smith Peter, Strayhorn Chris, Mizokami Atsushi, Fu Zheng, Westman John, Keller Evan T., Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the bone, 10.1172/jci11685
  26. Smith Matthew R, Saad Fred, Coleman Robert, Shore Neal, Fizazi Karim, Tombal Bertrand, Miller Kurt, Sieber Paul, Karsh Lawrence, Damião Ronaldo, Tammela Teuvo L, Egerdie Blair, Van Poppel Hendrik, Chin Joseph, Morote Juan, Gómez-Veiga Francisco, Borkowski Tomasz, Ye Zhishen, Kupic Amy, Dansey Roger, Goessl Carsten, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, 10.1016/s0140-6736(11)61226-9
  27. Bruland O. S., Nilsson S., Fisher D. R., Larsen R. H., High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the  -Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?, 10.1158/1078-0432.ccr-06-0841
  28. Henriksen G, Cancer Res, 62, 3120 (2002)
  29. Henriksen G, J Nucl Med, 44, 252 (2003)
  30. Lewington VJ, J Nucl Med, 46, 38S (2005)
  31. Liepe K, Curr Opin Investig Drugs, 10, 1346 (2009)
  32. McDevitt Michael R., Sgouros George, Finn Ronald D., Humm John L., Jurcic Joseph G., Larson Steven M., Scheinberg David A., Radioimmunotherapy with alpha-emitting nuclides, 10.1007/s002590050306
  33. Kerr Cathel, 223Ra targets skeletal metastases and spares normal tissue, 10.1016/s1470-2045(02)00835-5
  34. Li Yong, Russell Pamela J, Allen Barry J, Targeted α-therapy for control of micrometastatic prostate cancer, 10.1586/14737140.4.3.459
  35. Nilsson S., First Clinical Experience with  -Emitting Radium-223 in the Treatment of Skeletal Metastases, 10.1158/1078-0432.ccr-04-2244
  36. Nilsson Sten, Franzén Lars, Parker Christopher, Tyrrell Christopher, Blom René, Tennvall Jan, Lennernäs Bo, Petersson Ulf, Johannessen Dag C, Sokal Michael, Pigott Katharine, Yachnin Jeffrey, Garkavij Michael, Strang Peter, Harmenberg Johan, Bolstad Bjørg, Bruland Øyvind S, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study, 10.1016/s1470-2045(07)70147-x
  37. Parker Christopher C., Pascoe Sarah, Chodacki Aleš, O'Sullivan Joe M., Germá Josep R., O’Bryan-Tear Charles Gillies, Haider Trond, Hoskin Peter, A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer, 10.1016/j.eururo.2012.09.008
  38. Nilsson S., Strang P., Aksnes A.K., Franzèn L., Olivier P., Pecking A., Staffurth J., Vasanthan S., Andersson C., Bruland Ø.S., A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer, 10.1016/j.ejca.2011.12.023
  39. Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fosså S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall'Oglio M., Franzén L., Coleman R., Vogelzang N.J., O'Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø.S., Sartor O., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, 10.1056/nejmoa1213755
  40. Parker C., Gillessen S., Heidenreich A., Horwich A., Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 10.1093/annonc/mdv222
  41. Fizazi Karim, Beuzeboc Philippe, Lumbroso Jean, Haddad Vincent, Massard Christophe, Gross-Goupil Marine, Di Palma Mario, Escudier Bernard, Theodore Christine, Loriot Yohann, Tournay Elodie, Bouzy Jeannine, Laplanche Agnes, Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, 10.1200/jco.2008.18.9811
  42. Porter A.T., McEwan A.J.B., Powe J.E., Reid R., McGowan D.G., Lukka H., Sathyanarayana J.R., Yakemchuk V.N., Thomas G.M., Erlich L.E., Crook J., Gulenchyn K.Y., Hong K.E., Wesolowski C., Yardley J., Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, 10.1016/0360-3016(93)90309-j
  43. Rubini Giuseppe, Nicoletti Adriano, Rubini Domenico, Asabella Artor Niccoli, Radiometabolic Treatment of Bone-Metastasizing Cancer: From186Rhenium to223Radium, 10.1089/cbr.2013.1549
Bibliographic reference Dermine, Alexandre ; Machiels, Jean-Pascal. Treatment landscape of metastatic prostate cancer: the role of radium-223.. In: Acta Clinica Belgica, Vol. 72, no.1, p. 19-23 (2016)
Permanent URL http://hdl.handle.net/2078.1/182641